The fact that P-cad expression strongly correlates with unfavorable prognostic factors in ovarian cancer patients indicates that P-cadherin-targeted treatment benefits such a population, and the development of effective treatments may contribute to the improvement of survival. This evidence concerns the gene CDH3 and ovarian carcinoma.